Experimental Biology and Medicine · 2017 · 163 citations · 49 references
Life SciencesEndocrinologyNutritional SciencesMetabolic RegulationNutritional BiochemistryNutritional PhysiologyAdipose TissueDiabetes MellitusFatty Acid MetabolismInsulin ResistanceInsulin Signaling In MetabolismLipid MetabolismHepatic Lipid AccumulationIncreased AdiposityIntestinal Epithelial Barrier FunctionIntestinal Microbiota EffectsMetabolic Response To DietPancreatic Beta-cell FunctionPancreatic Beta-cell SecretionPancreatic Islet Cells
In this study, we investigated the effect of diet supplementation with sodium butyrate (5% w/w), a short-chain fatty acid produced by the intestinal microbiota, on metabolic parameters, body adiposity, hepatic and pancreatic lipid accumulation, beta cell function/mass as well as on the structure and function of the tight junction-mediated intestinal epithelial barrier in both normal and obese/prediabetic C57 mice fed a regular (control) or high-fat diet for 60 days, respectively. Butyrate treatment significantly inhibited all the high-fat-induced metabolic dysfunctions evaluated, i.e. significantly reduced the weight gain and body adiposity as well as the insulin resistant state, hyperglycemia and hyperinsulinemia, without changing food intake. In addition, high-fat-fed mice treated with this short-chain fatty acid displayed no compensatory hyperplasia of pancreatic beta cells nor marked hepatic steatosis as seen in prediabetic mice after high-fat diet only. Isolated pancreatic islets from high-fat-fed mice treated with butyrate showed improvement of the insulin secretion, which was associated with a significant decrease in lipid accumulation within the pancreas. Butyrate enhanced the intestinal epithelial barrier, as revealed by the FITC-Dextran permeability assay, which was accompanied by a significant increase in the junctional content of the tight junction-associated claudin-1 in intestinal epithelia of jejunum, ileum, and colon of both control and high-fat mice. In conclusion, our results showed that diet supplementation with butyrate inhibits the deleterious effects of high-fat diet intake on metabolic parameters and structure/function of several tissues/organs associated with type 2 diabetes mellitus in a mouse model, suggesting a potential use of this short-chain fatty acid in the treatment of this endocrine-metabolic disorder. Impact statement Butyrate is a short-chain fatty acid produced by the intestinal microbiota through the fermentation of non-absorbable carbohydrates and proteins (e.g. fibers). Sodium butyrate incorporated into the diet displayed a protective action on metabolic, hepatic, pancreatic and intestinal alterations induced by high-fat diet in mice, resulting in significant inhibition of the development of a prediabetic state. Thus, our data suggest that butyrate may have a potential therapeutic use in the treatment of type 2 diabetes and related disorders.
49
Metabolic Endotoxemia Initiates Obesity and Insulin Resistance
Patrice D. Cani, Jacques Amar, Miguel A. Iglesias et al. · Diabetes · 2007 · 6.4K citations · Full text
Diagnosis and Classification of Diabetes Mellitus
Diabetes Care · 2013 · 6K citations · Full text
Gut Microbiota in Human Adults with Type 2 Diabetes Differs from Non-Diabetic Adults
Nadja Larsen, Finn K. Vogensen, Frans van den Berg et al. · PLoS ONE · 2010 · 3K citations · Full text
Butyrate Improves Insulin Sensitivity and Increases Energy Expenditure in Mice
Zhan‐Guo Gao, Jun Yin, Jin Zhang et al. · Diabetes · 2009 · 2.2K citations · Full text